Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home
  
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Genetic Variant May Help Explain Why Labradors Are Prone To Obesity
A genetic variation associated with obesity and appetite in Labrador retrievers – the UK and US’s favourite dog breed – has been identified by scientists at the University of Cambridge. The finding may explain why Labrador retrievers are more likely to become obese than dogs of other breeds.
Scroll Up
Scroll Down

Return

Biomarkers in Late-Stage Clinical Trials: Applications, opportunities and activities of leading players
Bookmark and Share

Biomarkers reduce the attrition rate of late-stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of clinical trials, and help researchers complete the drug development process at a faster pace.

Scope of this research

  • Assessment of the revenues of late-stage biomarker technology and services in North America, Europe, Asia and the rest of the world.
  • Details of the key market drivers and restraints in the biomarker sector.
  • Information about microarrays, immunoassay, LC/MS and GC/MS, flow cytometry, imaging, PCR and services.
  • Patent analysis with respect to competitors and geography.
  • Discussion of major pharmaceutical companies, biotechs, contract research organizations and biomarker specialists.

Research and analysis highlights

The pharmaceutical and biotech sectors are currently facing increasing duration and cost issues related to clinical trials in drug discovery. Funding from government sources such as the National Institutes of Health has not increased significantly over the last few years.

More than 50% of clinical trials fail in Phase III for a host of reasons, including greater disease complexity, stiffer clinical endpoints, and the inability of the data to prove drug effectiveness.

Biomarkers play a crucial role in late-stage clinical trials by acting as surrogate endpoints for patient monitoring and stratification. Surrogate endpoints help measure treatment efficacy, and thus facilitate significant cost reductions in the drug development process.

Key reasons to purchase this research

  • Examine and evaluate the growth potential of emerging technologies.
  • Understand biomarker activity in the clinical trials of leading market players.
  • Gain knowledge about the relative importance of biomarker late-stage clinical trials technologies over the next five years.
  • Determine the collaborations and partnerships of the major market players.

Further Information


Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!